Cladribine, Low-Dose Cytarabine (LDAC), and Venetoclax (VEN) in Older/Unfit Acute Myeloid Leukemia (AML) Patients: A Single-Institution Experience

被引：0
|
作者：
Yohannan, Binoy [1 ]
Khan, Hina [1 ]
Cervoni-Curet, Frances [1 ]
Rios, Adan [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
AML; cladribine; low-dose cytarabine; older/unfit AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-100
引用
收藏
页码：S267 / S267
页数：1
相关论文
共 50 条
  • [41] Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
    Faderl, Stefan
    Ravandi, Farhad
    Huang, Xuelin
    Wang, Xuemei
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Ferrajoli, Alessandra
    Konopleva, Marina
    Borthakur, Gautam
    Burger, Jan
    Feliu, Jennie
    Kantarjian, Hagop M.
    CANCER, 2012, 118 (18) : 4471 - 4477
  • [42] Efficacy and Safety of Low-Dose Venetoclax Combined with Voriconazole Inpatients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
    Meng, Danchen
    Ruan, Min
    Liu, Xinyao
    Wu, Wei
    Zhuang, Junling
    Ge, Jian
    Huang, Zhenqi
    Long, Zhangbiao
    BLOOD, 2023, 142
  • [43] Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax
    Chan, Onyee
    Aguirre, Luis E.
    Burke, Mary
    Al Ali, Najla H.
    Xie, Zhuoer
    Yun, Seongseok
    Kuykendall, Andrew T.
    Padron, Eric
    Walker, Alison R.
    Lancet, Jeffrey
    Komrokji, Rami S.
    Sallman, David A.
    BLOOD, 2023, 142
  • [44] LOW-DOSE CYTARABINE IN THE TREATMENT OF ACUTE MYELOID-LEUKEMIA
    BERIS, P
    RIEDER, A
    ANDREY, C
    HELG, C
    CHAPUIS, B
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1984, 114 (48) : 1763 - 1766
  • [45] Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience
    Abu-Sayeef Mirza
    Seongseok Yun
    Najla Al Ali
    Hannah Shin
    Joseph Luke O’Neil
    Maher Elharake
    Daniel Schwartz
    Katherine Robinson
    Ethan Nowell
    Grace Engle
    Ibraahim Badat
    Thomas Brimer
    Amra Kuc
    Ashton Sequeira
    Sabbir Mirza
    Dhiraj Sikaria
    Jesus Diaz Vera
    Noah Hackney
    Sammy Abusrur
    Jose Jesurajan
    Jameson Kuang
    Shreyans Patel
    Sabrina Khalil
    Sonya Bhaskar
    Alexander Beard
    Toaa Abuelenen
    Kevin Ratnasamy
    Nathan Visweshwar
    Rami Komrokji
    Michael Jaglal
    Thrombosis Journal, 17
  • [46] Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience
    Mirza, Abu-Sayeef
    Yun, Seongseok
    Al Ali, Najla
    Shin, Hannah
    O'Neil, Joseph Luke
    Elharake, Maher
    Schwartz, Daniel
    Robinson, Katherine
    Nowell, Ethan
    Engle, Grace
    Badat, Ibraahim
    Brimer, Thomas
    Kuc, Amra
    Sequeira, Ashton
    Mirza, Sabbir
    Sikaria, Dhiraj
    Vera, Jesus Diaz
    Hackney, Noah
    Abusrur, Sammy
    Jesurajan, Jose
    Kuang, Jameson
    Patel, Shreyans
    Khalil, Sabrina
    Bhaskar, Sonya
    Beard, Alexander
    Abuelenen, Toaa
    Ratnasamy, Kevin
    Visweshwar, Nathan
    Komrokji, Rami
    Jaglal, Michael
    THROMBOSIS JOURNAL, 2019, 17 (1)
  • [47] Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
    Bashir, Yasir
    Geelani, Sajjad
    Bashir, Nusrat
    Mir, Shabeer A.
    Mushtaq, Mosin
    Jan, M. Aleem
    Rasool, Javid
    SOUTH ASIAN JOURNAL OF CANCER, 2015, 4 (01) : 4 - 6
  • [48] Venetoclax (Ven) with Azacitidine (Aza) for Untreated Elderly Acute Myeloid Leukemia (AML) Patients (Pts) Unfit for Induction Chemotherapy: Single Center Clinical Experience and Mechanistic Insights from Correlative Studies
    Pollyea, Daniel A.
    Stevens, Brett M.
    Winters, Amanda
    Minhajuddin, Mohd
    Gutman, Jonathan A.
    Purev, Enkhtsetseg
    Smith, Clayton
    Abbott, Diana
    Jordan, Craig T.
    BLOOD, 2017, 130
  • [49] Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)
    Kadia, Tapan
    Cortes, Jorge E.
    Jabbour, Elias J.
    Daver, Naval
    Pemmaraju, Naveen
    Ravandi, Farhad
    Jain, Nitin
    Verstovsek, Srdan
    DiNardo, Courtney
    Alvarado, Yesid
    Ferrajoli, Alessandra
    Burger, Jan A.
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Konopleva, Marina
    Estrov, Zeev
    Wierda, William
    Brandt, Mark
    Fitch, Tina
    Borthakur, Gautam
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [50] Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
    Sekeres, Mikkael A.
    Lancet, Jeffrey E.
    Wood, Brent L.
    Grove, Laurie E.
    Sandalic, Larissa
    Sievers, Eric L.
    Jurcic, Joseph G.
    HAEMATOLOGICA, 2013, 98 (01) : 119 - 128
12345